跳到正文
RadarAI· TechCrunch:AI(RSS)·· 6 小时前AI 评分74

Isomorphic Labs 完成 50 亿美元 C 轮融资,推进药物候选进入临床试验

AI 导读

从 Google DeepMind 分拆的 AI 药物发现公司 Isomorphic Labs 完成 50 亿美元 C 轮融资,由 Greenoaks 和红杉资本联合领投,a16z 等新投资方及 GV、Capital G 等现有股东参投。

正文 · 原文

TechCrunch:AI· Ram Iyer·2026-11-17 22:50· 26 分钟前AI 评分66

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

AI 导读

从 Google DeepMind 分拆的 AI 药物发现公司 Isomorphic Labs 完成 50 亿美元 C 轮融资,由 Greenoaks 和红杉资本联合领投,a16z 等新投资方及 GV、Capital G 等现有股东参投。

正文 · 原文

In Brief

Posted:

6:50 AM PST · November 17, 2026

Demis Hassabis, chief executive officer of DeepMind Technologies
Image Credits:Jose Sarmento Matos/Bloomberg / Getty Images
  • Ram Iyer

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

来源:TechCrunch:AI · techcrunch.com

事件后续 · 1

查看事件全部

来源:RadarAI · aihot.news